Rowan Saloner1,2, Mariana Cherner2, Jennifer E Iudicello2, Robert K Heaton2, Scott L Letendre2, Ronald J Ellis2,3. 1. San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA. 2. Department of Psychiatry, University of California, San Diego, HIV Neurobehavioral Research Program, San Diego, CA; and. 3. Department of Neurosciences, University of California, San Diego, CA.
Abstract
OBJECTIVE: HIV disease and methamphetamine (METH) dependence share overlapping mechanisms of neurotoxicity that preferentially compromise monoamine-rich frontostriatal circuitry. However, norepinephrine (NE) function is poorly understood in HIV and METH dependence. We evaluated associations between cerebrospinal fluid (CSF) NE and HIV, METH dependence, and neurocognition. METHODS: Participants included 125 adults, stratified by HIV serostatus (HIV+/HIV-) and recent METH dependence (METH+/METH-), who underwent comprehensive neurocognitive testing and lumbar puncture. CSF NE was assayed using high-performance liquid chromatography. Multivariable regression modelled NE as a function of HIV, METH, and their interaction, adjusting for demographic and clinical factors. Pearson correlations examined relationships between NE and demographically-adjusted neurocognitive domain scores. RESULTS: HIV significantly interacted with METH (P < 0.001) such that compared with HIV-/METH-, CSF NE was markedly elevated in the single risk-groups (HIV+/METH-: d = 0.96; HIV-/METH+: d = 0.79) and modestly elevated in the dual-risk group (HIV+/METH+: d = 0.48). This interaction remained significant after adjustment for lifetime depression, antidepressant use, and race/ethnicity. In the full sample, higher NE levels significantly correlated with worse global function (r = -0.19), learning (r = -0.23), and delayed recall (r = -0.18). Similar relationships between higher NE and worse neurocognition were detected in the METH- groups (ie, HIV-/METH- and HIV+/METH-) and in the virally-suppressed persons HIV+ subgroup, but not in the METH+ groups (ie, HIV-/METH+, HIV+/METH+). DISCUSSION: HIV and METH independently, but not additively, relate to noradrenergic excess in the central nervous system, and perturbations to noradrenergic function may represent a pathophysiological mechanism of HIV-related neurocognitive dysfunction. Consistent with prior reports that noradrenergic excess compromises hippocampal and prefrontal function, higher NE related to worse neurocognition, even among successfully treated persons with HIV. Pharmacological and psychosocial interventions that stabilize NE function may improve neurocognition in persons with HIV.
OBJECTIVE: HIV disease and methamphetamine (METH) dependence share overlapping mechanisms of neurotoxicity that preferentially compromise monoamine-rich frontostriatal circuitry. However, norepinephrine (NE) function is poorly understood in HIV and METH dependence. We evaluated associations between cerebrospinal fluid (CSF) NE and HIV, METH dependence, and neurocognition. METHODS: Participants included 125 adults, stratified by HIV serostatus (HIV+/HIV-) and recent METH dependence (METH+/METH-), who underwent comprehensive neurocognitive testing and lumbar puncture. CSF NE was assayed using high-performance liquid chromatography. Multivariable regression modelled NE as a function of HIV, METH, and their interaction, adjusting for demographic and clinical factors. Pearson correlations examined relationships between NE and demographically-adjusted neurocognitive domain scores. RESULTS: HIV significantly interacted with METH (P < 0.001) such that compared with HIV-/METH-, CSF NE was markedly elevated in the single risk-groups (HIV+/METH-: d = 0.96; HIV-/METH+: d = 0.79) and modestly elevated in the dual-risk group (HIV+/METH+: d = 0.48). This interaction remained significant after adjustment for lifetime depression, antidepressant use, and race/ethnicity. In the full sample, higher NE levels significantly correlated with worse global function (r = -0.19), learning (r = -0.23), and delayed recall (r = -0.18). Similar relationships between higher NE and worse neurocognition were detected in the METH- groups (ie, HIV-/METH- and HIV+/METH-) and in the virally-suppressed persons HIV+ subgroup, but not in the METH+ groups (ie, HIV-/METH+, HIV+/METH+). DISCUSSION: HIV and METH independently, but not additively, relate to noradrenergic excess in the central nervous system, and perturbations to noradrenergic function may represent a pathophysiological mechanism of HIV-related neurocognitive dysfunction. Consistent with prior reports that noradrenergic excess compromises hippocampal and prefrontal function, higher NE related to worse neurocognition, even among successfully treated persons with HIV. Pharmacological and psychosocial interventions that stabilize NE function may improve neurocognition in persons with HIV.
Authors: Kalpana J Kallianpur; Victor G Valcour; Sukalaya Lerdlum; Edgar Busovaca; Melissa Agsalda; Pasiri Sithinamsuwan; Thep Chalermchai; James L K Fletcher; Somporn Tipsuk; Cecilia M Shikuma; Bruce T Shiramizu; Jintanat Ananworanich Journal: AIDS Date: 2014-07-17 Impact factor: 4.177
Authors: J D Johnson; J Campisi; C M Sharkey; S L Kennedy; M Nickerson; B N Greenwood; M Fleshner Journal: Neuroscience Date: 2005-09-13 Impact factor: 3.590
Authors: Seetharamaiah Chittiprol; Adarsh M Kumar; P Satishchandra; K Taranath Shetty; R S Bhimasena Rao; D K Subbakrishna; Mariyamma Philip; K S Satish; H Ravi Kumar; Mahendra Kumar Journal: Psychoneuroendocrinology Date: 2007-11-13 Impact factor: 4.905
Authors: Jenna B Honeycutt; Angela Wahl; Caroline Baker; Rae Ann Spagnuolo; John Foster; Oksana Zakharova; Stephen Wietgrefe; Carolina Caro-Vegas; Victoria Madden; Garrett Sharpe; Ashley T Haase; Joseph J Eron; J Victor Garcia Journal: J Clin Invest Date: 2016-03-07 Impact factor: 14.808
Authors: Gail Ironson; Elizabeth Balbin; Emily Stieren; Kelly Detz; Mary Ann Fletcher; Neil Schneiderman; Mahendra Kumar Journal: Int J Behav Med Date: 2008
Authors: Ronald J Ellis; Meredith E Childers; Mariana Cherner; Deborah Lazzaretto; Scott Letendre; Igor Grant Journal: J Infect Dis Date: 2003-12-08 Impact factor: 5.226
Authors: Julie D Rippeth; Robert K Heaton; Catherine L Carey; Thomas D Marcotte; David J Moore; Raul Gonzalez; Tanya Wolfson; Igor Grant Journal: J Int Neuropsychol Soc Date: 2004-01 Impact factor: 2.892
Authors: Adam W Carrico; Emily M Cherenack; Leah H Rubin; Roger McIntosh; Delaram Ghanooni; Jennifer V Chavez; Nichole R Klatt; Robert H Paul Journal: Psychosom Med Date: 2022-08-28 Impact factor: 3.864